Insulin Diluting Medium For Garzulys Injection, Solution
Product Images NDC 71288-909

Product Visual Gallery

This gallery contains 37 technical images submitted to the FDA as part of the official labeling for Insulin Diluting Medium For Garzulys (NDC 71288-909). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Meitheal Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Fig1 Structure)

Chemical structure diagram showing the insulin aspart-fsan molecule, including labeled A-chain and B-chain amino acid sequences with disulfide bonds connecting specific cysteine residues.*

FDA Label Image

Figure 2 (Fig2)

A line graph depicting serum glucose levels (mg/dL) over time (hours). The x-axis represents time from 0 to 6 hours, and the y-axis represents serum glucose concentration from 50 to 300 mg/dL. Two lines show different glucose trends over the 6-hour period.*

FDA Label Image

Figure 3 (Fig3)

A line chart depicting mean blood glucose levels (mg/dL) over time (minutes). The x-axis shows time intervals before and after a reference point (R), with slashes indicating a jump in time. The y-axis ranges from 0 to 180 mg/dL, showing changes in glucose levels measured at these intervals, with error bars at each point.*

FDA Label Image

Figure 4 (Fig4)

A line graph depicting free serum insulin concentration (mU/L) over time (hours). The y-axis shows insulin levels ranging from 0 to 80 mU/L, and the x-axis represents time from 0 to 6 hours. Two curves are shown, one solid line peaking early and declining, and a dashed line with a lower peak and gradual decline, illustrating different pharmacokinetic profiles.*

FDA Label Image

Figure A (Ifu Pen Figure A)

An instructional illustration showing a person's hands holding a pen-like device, with the right hand pulling or sliding a transparent section to reveal internal components. The image is labeled with a capital letter 'A' in the upper left corner, indicating a step in a usage or preparation guide.*

FDA Label Image

Figure B (Ifu Pen Figure B)

Illustration of a hand holding an insulin pen with a blue arrow indicating the step to remove or turn the pen cap. The image is part of an instructional series demonstrating proper use of the device.*

FDA Label Image

Figure C (Ifu Pen Figure C)

Illustration showing a close-up of a hand holding a syringe with an arrow indicating a step, likely involving attachment or adjustment of a needle or cap, related to the preparation or administration of Garzulys injection solution.*

FDA Label Image

Figure D (Ifu Pen Figure D)

An instructional illustration showing a hand holding a syringe and attaching or preparing a small circular component at the needle end. The image is labeled with the letter 'D' in the upper left corner, indicating it is part of a step-by-step guide.*

FDA Label Image

Figure E (Ifu Pen Figure E)

An instructional illustration showing a person adjusting an injection pen, specifically selecting a dose of 2 units as indicated by an arrow and a label "2 units selected" on the pen's dose display. The fingers are shown turning the dosage selector on the pen.*

FDA Label Image

Figure F (Ifu Pen Figure F)

An instructional illustration showing a hand holding and shaking a small vial or pen device vertically. The image indicates a shaking motion, likely to mix the solution before use.*

FDA Label Image

Figure G (Ifu Pen Figure G)

An instructional diagram showing a hand holding and adjusting a pen-like injection device, presumably for Garzulys insulin aspart-fsan. The image highlights the dose adjustment by turning the dial on the pen with an arrow pointing upward. A smaller inset shows a close-up of the pen tip with a needle attached.*

FDA Label Image

Figure H (Ifu Pen Figure H)

An instructional illustration demonstrating how to select insulin dosage units on a pen injector. The image shows hands adjusting the dial to select 5 units and 24 units of insulin, with zoomed-in insets highlighting the selected unit numbers on the dosing window.*

FDA Label Image

Figure I (Ifu Pen Figure I)

An instructional illustration showing a hand holding an injection pen or vial with a cap. The image indicates pressing down on the cap with a downward arrow, suggesting how to remove or secure the cap. A small icon in the corner shows a graphic of the cap removal forward motion.*

FDA Label Image

Figure J (Ifu Pen Figure J)

An illustration of a medical injection pen or syringe device poised above skin, presumably showing the proper technique for subcutaneous or intravenous administration. The device is depicted with a visible dosage window and a needle at the tip.*

FDA Label Image

Figure K (Ifu Pen Figure K)

An instructional illustration showing hands holding a pen-type injector, with an arrow indicating the movement needed to pull or slide a component of the injector. The image likely depicts a step in preparing or using the injection device for Garzulys (insulin aspart-fsan).*

FDA Label Image

Garzulys Prefilled Pen (Ifu Pen Image)

An instructional diagram of the Garzulys Prefilled Pen insulin injection device. It labels components including the pen cap, rubber stopper, cartridge, cartridge scale, pointer, dose selector, and push-button, illustrating the main parts for dose selection and administration.*

FDA Label Image

Garzulys Needles (Ifu Pen Needles)

An instructional diagram showing components of NovoFine and NovoFine Plus needles, including the big outer needle cap, inner needle cap, needle, and protective tab for each type. The illustration depicts the layout and names of each part separately for both needle types.*

FDA Label Image

Places To Inject (Ifu Pen Places To Inj)

An anatomical diagram showing front and back views of a human figure with shaded areas indicating common injection sites. These include the abdomen, upper arms, thighs, and buttocks, illustrating recommended locations for subcutaneous or intravenous injection administration.*

FDA Label Image

Garzulys Vial Diagram (Ifu Vial Diagram)

An illustration depicting a vial with labeled components including a tamper-resistant cap and a rubber stopper located under the cap.*

FDA Label Image

Figure A, Figure B (Ifu Vial Figure A B)

Instructional line drawings showing two hands removing a cap from a small vial to prepare it for use. The vial is held upright and the cap is pulled off carefully. This likely demonstrates part of the medication preparation procedure for an injectable drug.*

FDA Label Image

Figure C (Ifu Vial Figure C)

An instructional line drawing showing a hand holding a syringe to prepare an injection. A smaller inset shows the syringe filled with medication. The image illustrates how to handle or prepare the syringe for use, relevant to Garzulys insulin aspart-fsan injection, solution.*

FDA Label Image

Figure D (Ifu Vial Figure D)

A line drawing illustration showing hands withdrawing liquid from a vial into a syringe. This instructional image depicts the proper technique of preparing an injection, likely for the Garzulys insulin aspart-fsan injection solution.*

FDA Label Image

Figure E (Ifu Vial Figure E)

An illustration showing hands preparing a syringe and vial, likely for injection. One hand holds a vial while the other hand draws liquid into the syringe, indicated by an arrow pointing away from the vial toward the syringe plunger.*

FDA Label Image

Figure F (Ifu Vial Figure F)

An instructional illustration showing two hands preparing an injection device. One hand holds a vial inverted, connected to a syringe or similar apparatus, while the other hand is positioned to draw liquid into the syringe, indicated by a downward arrow.*

FDA Label Image

Figure G (Ifu Vial Figure G)

An instructional illustration showing a pair of hands preparing an injection solution. One hand holds an inverted vial attached to a syringe, while the other hand appears to adjust or push the syringe plunger. The image likely demonstrates proper technique for drawing medication into a syringe.*

FDA Label Image

Figure H (Ifu Vial Figure H)

An instructional illustration showing a person drawing liquid medication from a vial into a syringe. The main image shows hands holding a vial upside down with the syringe inserted into the vial. An inset detail highlights the syringe barrel with measurement markings, indicating the process of withdrawing a measured dose.*

FDA Label Image

Figure I (Ifu Vial Figure I)

An instructional illustration showing a hand holding a vial and another hand withdrawing solution into a syringe. The arrow indicates the direction for pulling the syringe plunger to draw liquid from the vial, demonstrating proper technique for preparing an injection.*

FDA Label Image

Figure J (Ifu Vial Figure J)

An instructional illustration showing recommended injection sites on a human male figure. Highlighted areas include the stomach, outer upper arms, front thighs, and buttocks, indicating suitable locations for subcutaneous injection administration.*

FDA Label Image

Figure K (Ifu Vial Figure K)

An instructional illustration showing how to properly hold a syringe to administer an injection, with one hand holding the syringe and the other preparing the injection site on the skin. No specific branding or text visible.*

FDA Label Image

Figure L (Ifu Vial Figure L)

An instructional illustration showing a hand holding a syringe poised for injection into the skin of a person's arm, demonstrating subcutaneous administration technique.*

FDA Label Image

Garzulys With Hand (Ifu Vial With Hand)

Illustration of a hand holding a small vial, depicting the proper grip or handling of the Garzulys injection solution vial containing insulin aspart-fsan, 1 mL/mL, 100 units per mL, by Meitheal Pharmaceuticals Inc.*

FDA Label Image

Principal Display Panel – Garzulys (insulin Aspart-fsan) Injection 100 Units Per mL Pen Carton (Pen 100u Carton V5)

Packaging label for Garzulys (insulin aspart-fsan) injection 100 units/mL (U-100), 5 x 3 mL prefilled pens. The label indicates single patient use only and for subcutaneous use. It is manufactured for Meitheal Pharmaceuticals Inc. The label includes storage and usage warnings, ingredient details, and a barcode.*

FDA Label Image

Principal Display Panel – Garzulys (insulin Aspart-fsan) Injection 100 Units Per mL Pen Label (Pen 100u Label V4)

Label for Garzulys (insulin aspart-fsan) injection solution, 100 units/mL (U-100). It is presented as a 3 mL prefilled pen for subcutaneous use. The label states "For Single Patient Use Only" and includes storage instructions to refrigerate and protect from light. Manufactured by Emerge Bioscience Pte. Ltd., Singapore, and labeled by Meitheal Pharmaceuticals Inc. The label also shows the NDC 71288-903-80, lot number ABC123, and expiration date 2027-10-31.*

FDA Label Image

Principal Display Panel – Garzulys (insulin Aspart-fsan) Injection 100 Units Per mL Vial Carton (Vial 100u Carton V5)

Packaging label for Garzulys (insulin aspart-fsan) injection, 100 units/mL (U-100), a solution for subcutaneous or intravenous use. The label indicates a 1 x 10 mL multiple-dose vial. Manufactured for Meitheal Pharmaceuticals Inc., the label includes drug details, storage instructions, warnings, and a barcode.*

FDA Label Image

Principal Display Panel – Garzulys (insulin Aspart-fsan) Injection 100 Units Per mL Vial Label (Vial 100u Label V4)

Label for Garzulys insulin aspart-fsan injection, 100 units/mL (U-100) in a 10 mL multiple-dose vial. Indicated for subcutaneous or intravenous use. Labeled by Meitheal Pharmaceuticals Inc., manufactured by Emerge Bioscience Pte. Ltd. Includes storage instructions and lot number ABC123 with expiration date 2027-10-31.*

FDA Label Image

Principal Display Panel – Garzulys (insulin Aspart-fsan) Injection Vial Diluent Carton (Vial Diluent Carton V5)

Packaging label for Insulin Diluting Medium for Garzulys, a multiple-dose vial with 1 x 10 mL. The label emphasizes that this product does not contain insulin and is for use only with Garzulys. It includes caution and storage instructions, ingredients of the diluting medium, and manufacturer information from Meitheal Pharmaceuticals Inc.*

FDA Label Image

Principal Display Panel – Garzulys (insulin Aspart-fsan) Injection Vial Diluent Label (Vial Diluent Label V4)

Label for Insulin Diluting Medium for Garzulys, a 10 mL multiple-dose vial. The label states it is to be used only with Garzulys and clarifies that this product does not contain insulin. Storage instructions include refrigeration between 2°C to 8°C, protection from light, and a warning about the vial closure not being made with natural rubber latex. The label also includes manufacturer details for Meitheal Pharmaceuticals Inc. and related lot and expiration information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.